Andexanet alfa versus 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in patients with intracranial hemorrhage; a systematic review and meta-analysis

Introduction Andexanet alfa is a specific antidote for factor Xa inhibitors. However, its availability is restricted in various countries, leading to the utilization of 4-factor prothrombin complex concentrate (4F-PCC) as an alternative. This study aims to compare the efficacy of andexanet alfa versus 4F-PCC in patients with factor Xa inhibitor-associated intracranial hemorrhage (ICH).